Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, tofacitinib treatment for six months significantly reduced hair loss severity in alopecia areata patients.

This case report described a 24-year-old with alopecia totalis who saw full scalp hair regrowth by the 9th month while using oral tofacitinib, which was well-tolerated and did not show serious adverse effects. Longer-term studies are needed to confirm its overall effectiveness for alopecia totalis.

This study found that ocu-miR-205 promotes the apoptosis of dermal papilla cells and the transformation of hair follicles from growth to regression and resting phases in Rex rabbits.

RV3466F lotion significantly reduces hair loss and improves acute telogen effluvium.

This source reports that while creatine supplementation is popular for improving muscle mass and performance, questions about its efficacy and safety persist. An expert team is reviewing literature to address concerns like water retention, renal effects, and its benefits across different populations and uses.

This study found that treatment with ritlecitinib or brepocitinib was effective in improving scalp hair loss for patients with alopecia areata over 24 weeks compared to placebo.

This article reports a case of rhabdomyolysis in a patient two hours after consuming the freshwater fish Mylossoma duriventre, suggesting a possible link to Haff disease from an unidentified toxin.

This review highlights that while sonidegib and vismodegib offer promising treatment options for advanced basal cell carcinoma, their use is often limited by treatment-emergent adverse events, which can be managed through protocol modifications and supportive interventions.

This review summarized the latest knowledge suggesting that Janus kinase inhibitors may have therapeutic potential for treating skin diseases like atopic dermatitis and psoriasis, especially when conventional therapies do not work.

This review discusses the use of Janus kinase inhibitors for severe alopecia areata in Japan, noting their effectiveness in some patients but highlighting the need for new therapies due to non-responsiveness and relapse in others; it reports no new clinical results.

This study reviewed various studies and concluded that Janus kinase inhibitors, particularly tofacitinib, seem to promote hair regrowth in about half of patients with alopecia areata, though expected class-specific adverse effects were observed.

This article describes the development milestones and recent approvals of ritlecitinib for treating severe alopecia areata, with approvals in the USA and Japan and ongoing regulatory reviews in other regions.

This study found that the oral JAK1/JAK2 inhibitor deuruxolitinib effectively promoted hair regrowth and patient satisfaction in adults with alopecia areata over 24 weeks.

In this study, ritlecitinib showed sustained effectiveness and a favorable safety profile in treating alopecia areata in patients aged 12 and older over 24 months, with improvements observed in hair and eyebrow regrowth and patient satisfaction.

In this randomized, placebo-controlled trial, adults with severe chronic alopecia areata who received deuruxolitinib showed significant hair regrowth compared to placebo over 24 weeks, and the treatment was generally well-tolerated, though long-term effects remain unexamined.

This review concluded that baricitinib and other oral JAK inhibitors have the most robust evidence supporting their use in treating severe alopecia areata in adults, compared to other less-evaluated treatments.

This study reviewed the burden of alopecia areata in the UAE, noting limited regional data on patient demographics and treatments but highlighting the approval and promising results of the Janus kinase inhibitor baricitinib for managing this condition.

In this case report, a woman with ulcerative colitis experienced clinical deterioration during upadacitinib therapy, which improved after discontinuation, strongly suggesting drug hypersensitivity to the Janus kinase inhibitor as a potential cause for her symptoms.

This review examines clinical data on the efficacy and safety of JAK inhibitors used for immune-mediated conditions beyond rheumatoid arthritis, highlighting their potential therapeutic roles in various inflammatory diseases.

This review evaluates existing research on Keratin 15 to assess its validity as a marker for epidermal stem cells, reporting no new results.

This review explores animal models of alopecia areata, particularly focusing on the insights they've provided into the disease's immune mechanisms and potential treatment approaches, without reporting new experimental data.

This review discusses recent advances and ongoing clinical trials in novel therapeutics for alopecia areata, despite the lack of current FDA-approved treatments for severe cases, and reports no new results.

This study found that biallelic mutations in the TTC7A gene affect lymphocyte and gut epithelial cell function, thereby contributing to the development of inflammatory bowel disease in patients.

This review discusses the role of the TCL1 transgenic mouse model in understanding chronic lymphocytic leukemia biology and highlights the importance of exploring new pathogenetic and therapeutic targets.

This review explored the new and emerging treatments for androgenetic alopecia and alopecia areata, finding that JAK inhibitors show promise for alopecia areata, while advancements in stem-cell research may eventually lead to new and improved treatments for androgenetic alopecia.

This review outlines dermatological toxicities associated with targeted cancer therapies and immunotherapies, emphasizing the need for collaborative management by oncologists and dermatologists but reports no new clinical findings.

This study reported that baicalin activates the Wnt/β-catenin signaling pathway in mouse hair follicles, suggesting its potential as a topical treatment for hair loss.

This study found that ILK deficiency disrupts hair follicle development by impairing cell polarity and laminin-511 assembly, but these defects can be partially reversed with exogenous laminin-511.

This review examines the outcomes of treating Brazilian patients with alopecia universalis using tofacitinib and highlights the need for randomized controlled trials to determine optimal dosing and duration.

This study highlights that while there are no FDA- or ANVISA-approved treatments for children with alopecia areata, JAK inhibitors are emerging as a promising therapeutic option for this population.